Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05192642 · ClinicalTrials.gov registry record
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 368
- Enrollment target
NCT05192642: Completed study, sponsored by Bayer.
NCT05192642 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 368 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05192642 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 368 participants
- Enrollment target
Study Summary
This is an observational study in which patient data from the past of adult people with solid tumors harboring NTRK gene fusion are studied. This study will focus on 5 tumor types which have been at the late stage or have spread to other parts of the body. These 5 tumor types are: * Non-small-cell-lung cancer * Colorectal cancer (located in the intestine) * Thyroid cancer * Sarcomas (located in the connective tissue like bones or body fat) * Salivary gland carcinoma In some people with cancer, the cancer cells have specific changes in their building plans (genes) called NTRK gene fusion. NTRK stands for neurotrophic tyrosine receptor kinase, the specific gene that is changed. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive. While NTRK is the gene, TRK (tropomyosin receptor kinase) is the name of the protein. The specific cancer is therefore also called TRK fusion-positive cancer. The study drug, larotrectinib works by blocking the altered TRK fusion protein. Larotrectinib is already available in the US, Europe, and in other countries and is approved for doctors to prescribe to patients with TRK fusion cancer. The main purpose of this study is to learn more about how well larotrectinib works in adults with TRK fusion-positive cancer compared to other treatments. Researchers will compare how long participants who received larotrectninib lived to how long participants who received other treatments lived. To do this, larotrectinib data from past clinical studies will be compared with data on other treatments gathered from different health data sources. The data will cover the time between January 2013 and end of August 2022. Besides this data collection, no further tests or examinations are planned and no visits are required in this study.
Interventions
- DRUG Larotrectinib(Vitrakvi, BAY2757556)
- DRUG Data on other treatments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2021-12-03 |
| Est. Completion | 2023-08-31 |
What the finished NCT05192642 record still lists
NCT05192642 is an observational study that tracks outcomes without assigning an intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Larotrectinib(Vitrakvi, BAY2757556) is the first listed.
NCT05192642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05192642 about?
NCT05192642 is a clinical study titled "A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice". This is an observational study in which patient data from the past of adult people with solid tumors harboring NTRK gene fusion are studied. This study will focus on 5 tumor types which have been at the late stage or have spread to other parts of the body. These 5 tumor types are: * Non-small-cell-...
What is the current status of trial NCT05192642?
This trial is currently completed. The enrollment target is 368 participants. The study started on 2021-12-03. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05192642?
The interventions under investigation include: Larotrectinib(Vitrakvi, BAY2757556) (DRUG), Data on other treatments (DRUG).
Who is sponsoring clinical trial NCT05192642?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI